MedWatch

Fujifilm's factory in Denmark generates USD 430m revenue

Fujifilm Diosynth Biotechnologies, a Japan-based company that produces drugs for other firms, has released its first annual accounting report since it started operating in Denmark. This comes two years after the company bought a medicine factory in the country.

Lars Petersen, CEO of Fujifilm Diosynth Biotechnologies in Denmark | Photo: Fujifilm Diosynth Biotechnologies

Two years after Fujifilm Diosynth Biotechnologies (FDB) spent DKK 6bn (USD 960m) on a medicine factory in Northern Zealand, Denmark, the contract producer has released its first annual accounting report for its Danish operations.

The report reveals a DKK 2.7bn (USD 430m) revenue and a profit of just over DKK 100m (USD 16m), Danish media Dagbladet Børsen writes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs